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human genome sequence in an accurate and timely fashion at a moderate cost. Specifically, next-generation sequencing (NGS) methods are currently available for clinical testing of either candidate gene panels or the entire human exome (ie, the portion of the genome translated to protein function). The results of such testing could inform practitioners on better ways to diagnose disease and to treat patients. Currently, many commercial and institutional laboratories across the United States offer College of American Pathologists/ Clinical Laboratory Improvement Amendments (CAP/CLIA)ecertified NGS-based tests for diagnostic purposes. Their cost ranges from $500 to $3000 for gene panel testing and from $7000 to $12,000 for whole exome sequencing (WES).
In this synopsis, we provide an update of the genetic basis of selected digestive diseases, namely, inflammatory bowel disease (IBD), hereditary cholestatic liver disease, and colon cancer and polyposis syndromes. Moreover, we provide an approach on how to apply these NGS methods aimed at improving the diagnosis and hopefully therapy of these conditions.
INFLAMMATORY BOWEL DISEASES
Inflammatory bowel diseases, including ulcerative colitis (UC) and Crohn disease (CD), are chronic relapsing and remitting diseases that result in immune-mediated damage to the gut and other organs or systems. The incidence and prevalence of both CD and UC have increased significantly during the 20th century (P<.05). 1 For example, in Olmsted County, Minnesota, the incidence of CD increased from 5.8 to 133 cases per 100,000 person-years 2 and that of UC increased from 7.6 to 299 cases per 100,000 person-years between 1940 and 1991. 3 A more recent update has suggested that this increase has now plateaued. 4 Nevertheless, there is a considerable heterogeneity in the severity and behavior of IBD among patients. For example, some patients exhibit a stable inflammatory course whereas others have more complicated outcomes with penetrating (ie, fistula and abscess) or fibrotic (ie, stricture) behavior, leading to the need for surgery and significant morbidity. 5 
Gamut of IBD Presentations and Opportunities During the Genomic Era
Recent advances in understanding the pathogenesis of IBD have identified at least 163 genetic loci associated with this group of disorders. 6 It is believed that IBD occurs in an individual as a result of complex genetic, environmental, and microbial factors, leading to chronic inflammatory tissue damage. 7 With the recognition that IBD is a broad group of disorders with significant interindividual differences in etiology and disease behavior, it seems intuitive that genomic testing could be incorporated into clinical practice to stratify genetic causation or contribution of disease and to individualize treatment strategies. Currently, the main use of genetic testing in routine clinical practice for patients with IBD is limited to pharmacogenomics 8 and possibly to predict disease behavior. 9, 10 Moving forward, studies that confirm the effectiveness of therapies designed specifically for subgroups of patients with IBD on the basis of genetic and other (ie, epigenome, microbiome, and metabolomics) factors will greatly expand the role of genomic testing in clinical management.
The use of comprehensive genomic testing for IBD (as opposed to targeted genotyping such as for thiopurine transmethyltransferase before the use of thiopurines) is already being incorporated into clinical practice in specific scenarios. This applies to specific groups of patients including those with very early onset inflammatory bowel disease (VEOIBD). These are patients with a family history of IBD that suggests Mendelian inheritance as well as IBD development with severe and refractory behavior. In such situations, genomic testing is used to search for monogenic disorders that have manifestations similar to those of typical IBD but will require a different therapeutic approach. The goal is to make a diagnosis owing to a specific genomic cause (as opposed to IBD) and thus to improve therapy. Very early onset inflammatory bowel disease (defined as onset of IBD by 6 years of age) is a particularly compelling example of how this approach can lead to more effective individualized therapies in patients who are usually extremely ill. These young children with manifestations of IBD tend to exhibit disease behavior that differs from and is more severe than that of patients with classic IBD. Although the incidence of IBD is increasing in all age groups, it appears to be increasing at the highest rate in patients with VEOIBD.
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Phenotypic differences include a much higher percentage of patients with colon-only involvement (as high as 80% with CD) and more extensive colon participation (ie, pancolitis). 12, 13 There is also a much higher rate of refractoriness to conventional medical therapies, higher rates of hospitalization, and more commonly a positive family history of IBD. 13 All these facts might lead one to expect that there is a greater genetic influence on the development of VEIOBD with genomic loci that are unique from other forms of IBD.
Surprisingly, genome-wide association studies 14, 15 of pediatric IBD, including one 16 that focused on VEOIBD, have essentially replicated findings from adult studies. However, when this is approached at the level of an individual patient or family, rare monogenic diseases can be identified, leading to a new diagnosis. In addition, several diseases in young children can exhibit enteropathy that mimics IBD. 17 This is a diverse group of disorders including defects in T-or B-cell function, phagocytes, epithelial barrier, and autoimmune or hyperinflammatory disorders. The current clinical use of WES in combination with more conventional diagnostic approaches is becoming increasingly useful, given that at least 50 distinct but rare diseases and genetic defects can present with a VEIOBD phenotype (Figure) . 18 When faced with such a deep and diverse differential diagnosis, the clinical utility of WES eventually becomes more efficient and cost-effective than that of piecemeal sequencing of single genes.
Assessing IBD in Clinical Practice Using Genomic Testing
In the current clinical practice of selected patients with IBD who may benefit from genomic testing, we use the following approach: First, "gene panel" testing is used that is focused on specific known IBD loci, which requires less expertise to synthesize and report results. In our practice, the Emory Genetics Laboratory has selected the NGS-based CAP/CLIA-certified IBD gene panel that includes a deletion and duplication panel covering 26 Incorporating WES into the clinical care of patients with IBD requires multifaceted expertise beyond the scope of most practicing gastroenterologists. Our approach has been to assemble a multidisciplinary group of physicians with expertise in adult and pediatric IBD, immunology, and genetics who provides a comprehensive clinical evaluation and represents a special interest hub within Mayo's Individualized Medicine (IM) Clinic. 20 Members of this group are clinicians who are most likely to be the point of referral for patients who would most benefit from an approach that incorporates WES into clinical practice. Such referrals include patients with VEOIBD, children and adults with IBD that is refractory to conventional therapies, and families who have multiple members affected with IBD. A comprehensive clinical evaluation is then performed in parallel with genomic testing.
Components of the initial evaluation include all things typically required in the care of patients with complex IBD, including an adult or pediatric gastroenterology consultation, a comprehensive survey of disease burden (eg, endoscopy, colonoscopy, and enterography), and additional consultations based on individual needs (eg, rheumatology and colorectal surgery). For patients identified as candidates for IM clinic evaluation, an immunology consultation is requested. A careful immunology evaluation may lead to a new diagnosis through immunophenotyping and/or targeted sequencing of 1 or 2 genes when a compelling pattern is identified (eg, identification of chronic granulomatous disease by exhibiting impaired neutrophil oxidative burst). This is rare, and genomic testing can be incorporated into the evaluation to extend the scope of investigation. Finally, patients who undergo WES meet with a certified genetic counselor of the IM clinic to discuss expectations, limitations, and risk of this testing.
Genomic testing such as WES has historically been performed under the auspices of research. This is now widely available from several commercial or institutional clinical laboratories meeting the regulatory requirements for patient care. Challenges of the practitioners using WES in the clinical setting include insurance coverage, incorporation of the genomic FIGURE. Several specific mechanisms are likely involved in the development of very early onset inflammatory bowel disease (VEOIBD). These include defects of epithelial barrier in the intestine, defects of phagocytosis, defects of T cells and/or B cells, dysregulation of the immune system, defects in genes of rare monogenic disorders and defects in genes of other hyper or autoimmune diseases.
results into the EHR, and interpreting and reporting complex results to patients. Beyond identifying pathogenic or likely pathogenic variants relevant to the clinical question at hand, WES will report many other variants that require specialized expertise to interpret. This includes medically actionable incidental findings, alleles with pharmacogenomic importance, carrier status, and variants of uncertain significance. We recently reported our experience incorporating WES into clinical care. 21 Our IM clinic uses a genomics odyssey board (GOB) to review WES results and generate clinical and pharmacogenomic reports for the patients tested. This is a multidisciplinary board of genomic medicine experts from across the institution, including members from molecular genetics, clinical genome sequencing laboratory, bioinformatics, and bioethics. The findings of the GOB are incorporated into the EHR. Clinicians can then communicate these results with the assistance of a certified genetic counselor and use this information in clinical practice.
Paradigms of Applying NGS for Patients With IBD or IBD-Like Phenotype
One example of how this approach can be applied in the clinic is an adolescent male patient who was seen for a second opinion regarding lifelong enteropathy, stunting, arthritis, uveitis, and dermatologic manifestations. Previous extensive single gene testing was not revealing. Whole exome sequencing was performed in a commercial CAP/CLIAcertified laboratory, and the results were reviewed at the GOB. Whole exome sequencing identified a novel genetic defect in the lipopolysaccharide responsive beigelike anchor (LRBA) gene. Other mutations in the LRBA gene have been associated with immunodeficiency and autoimmunity. 22 Ultimately, because of the scientific discussions that took place during the GOB meetings, a collaboration was established with other centers that had additional patients with LRBA defects and were exploring its function. Functional studies report that loss of LRBA resulted in deranged intracellular trafficking of cytotoxic T lymphocyte antigen 4. As a result of these observations, our patient and others from outside medical centers with LRBA defects were treated with abatacept (a fusion protein linking the extracellular domain of cytotoxic T lymphocyte antigen 4 and the fragment crystallizable region of human immunoglobulin G subclass 1), with significant improvement in their symptoms. The experience of the collaborative group was recently reported. 23 The approach just described is limited by the resources required and is applied only to selected cases with a high likelihood of diagnostic yield.
Both gene panel testing and WES in selected patients with IBD can lead to actionable results as described previously and can be performed as a part of the patient's clinical care. Clinical genomic testing can identify rare but well-characterized diseases with established therapeutic approaches not typically used in IBD. This approach is also not limited to pediatrics. For example, gene panel testing or WES in patients seen in our adult IBD clinic has identified individuals with defects in the interleukin 10 receptor and forkhead box P3.
Overall, the use of genomic testing can provide a specific understanding of pathogenesis for patients with IBD in selected clinical scenarios. This may allow selection of more targeted therapies for that individual, provide a more accurate prognosis, and be useful for genetic counseling about other relatives or future pregnancy. Thus, as availability and cost continue to improve, NGS-based genomic testing will become a common part of clinical care of patients with IBD.
HEREDITARY CHOLESTATIC LIVER DISEASE
Chronic cholestasis is a serious and devastating component of both pediatric and adult liver diseases that is either inherited or acquired. 24 Clinically, cholestasis is defined by increased serum hyperbilirubinemia and increased alkaline phosphatase levels due to impairment of bile flow. Anatomically, cholestasis is categorized as intrahepatic (caused by a diverse group of hepatobiliary diseases with overlapping clinical presentations) or extrahepatic (largely due to obstructive lesions of the bile ducts outside the liver). From a pathogenesis standpoint, several causes of chronic cholestasis are genetic in origin (Table 2 ). For example, neonatal cholestasis (jaundice due to conjugated bilirubin that lasts longer than 2-3 weeks after birth) is due to genetic and/or metabolic causes in about 25% to 30% of the affected patients. 26 Neonatal cholestasis (incidence of 1 in 2500 live births) represents a severe medical condition that needs immediate attention and intervention to avoid permanent liver and other organ damage. 26 This review will focus on the pathogenesis and diagnosis of hereditary forms of intrahepatic cholestatic liver disease, such as neonatal cholestasis, that usually present very early in childhood. Of interest, chronic cholestasis in some adults is caused by mutations in the genes known to be involved in neonatal cholestasis. Therefore, this article aims to educate practitioners on this topic and to provide an approach of genomic testing for these conditions in clinical practice. a 1 -Antitrypsin Deficiency This is the most common cause of inherited neonatal cholestasis. It affects about 10% to 15% of neonates and is manifested by elevation of the alanine transaminase, aspartate transaminase, gamma-glutamyltranspeptidase, and alkaline phosphatase levels in serum.
Cholestasis is usually severe, and the presence of acholic stools makes it challenging to differentiate from biliary atresia. Some patients may develop cirrhosis early in life; however, jaundice disappears in most patients by 4 months of age. 27 The diagnosis is made on the basis of the phenotype (normal: MM; abnormal: ZZ or SZ; heterozygous: MZ and MS). 28 Neonates with ZZ phenotype may have no biliary excretion on scintigraphy, 29 and liver biopsy may appear obstructive. 30 Checking for serum levels of a 1 -antitrypsin could be helpful if used along with the phenotype to distinguish patients who are homozygous for the Z allele or SZ compound heterozygotes, both of whom may develop liver disease. Patients with MZ, MS, SZ, or homozygous SS phenotypes do not present with neonatal cholestasis unless associated with another cause. 31 Serum a 1 -antitrypsin concentrations alone are an insufficient test because a 1 -antitrypsin is an acute phase reactant and, during illnesses, may be increased in serum. 32, 33 Alagille Syndrome This is a rare (1 in w30,000 live births) autosomal dominant condition affecting multiple organs. Patients have paucity of bile ducts (ductopenia on liver biopsy), leading to cholestasis, heart defects (commonly peripheral pulmonic stenosis or tetralogy of Fallot 34 ), characteristic face (broad forehead or small pointy chin), and skeletal abnormalities (butterfly vertebrae). The diagnosis of Alagille syndrome is usually made on the basis of clinical as well as laboratory findings and is confirmed by the presence of mutations in iagged 1 (95% of patients) and neurogenic locus notch homolog protein 2 (5% of patients) genes. 35 Because of chronic cholestasis, patients have pruritus, fat malabsorption, growth failure, metabolic bone disease, and xanthomas. 36 Only about 50% of patients survive into adulthood without liver transplant. 37 However, liver transplant in these patients is challenging because of preexisting cardiac defects.
Progressive Familial Intrahepatic Cholestasis
Among the hereditary forms of intrahepatic cholestatic liver disease, progressive familial intrahepatic cholestasis (PFIC) comprises a collection of autosomal recessive inherited diseases, which usually present in infancy or childhood. 38 The estimated incidence is about 1 per 50,000 to 100,000 live births. 38 To date, the 3 PFIC disorders have been characterized and include familial intrahepatic cholestasis type 1 deficiency, bile salt export protein deficiency, and multidrug resistance 3 (MDR3) deficiency. These diseases are due to mutations in specific genes involved in the formation and transport of bile acids (Table 2) . Each condition displays distinctive clinical and laboratory features and may progress to liver failure at different rates (Table 3) . Progressive familial intrahepatic cholestasis type 1 (formerly known as Byler disease) is recently renamed as familial intrahepatic cholestasis deficiency and is caused by mutations in the ATPase phospholipid transporting 8B1 (ATP8B1) or familial intrahepatic cholestasis 1 gene. 40 Progressive familial intrahepatic cholestasis type 2 (previously known as Byler syndrome) is now termed bile salt export protein deficiency after the identification of mutations in the ATP binding cassette subfamily B member 11 (ABCB11). gene among these patients, which encodes a protein serving as a bile salt export pump. 41 Finally, PFIC type 3 is due to defects in the class III multidrug resistance P-glycoprotein (MDR3) or ATP binding cassette subfamily B member 4 (ABCB4). gene and is currently called MDR3 deficiency. 42 Since the discovery of these genes, it has become evident that PFIC disorders represent a phenotypic continuum from mild to severe phenotypes of cholestasis. Of interest, patients with such genetic defects may be diagnosed later in life beyond childhood. Therefore, awareness of the disease spectrum as well as familiarity with novel gene panel testing for these conditions are important elements for diagnosing PFIC among practicing hepatologists. Despite this progress, about 30% of patients with a PFIC phenotype have no mutations in any of the genes listed previously. 38 In such cases, the application of WES has the potential to discover novel genes that contribute to the development of PFIC. Such new knowledge could lead to better diagnosis and management of these patients.
Bile Acid Synthesis Disorders
More than a dozen enzymes participate in the synthesis of bile acids from cholesterol. 43 Although rare, bile acid synthesis disorders are treatable forms of cholestasis in many cases. Of interest, not every infant with genetic abnormalities leading to bile acid synthesis disorders develops cholestasis and jaundice. However, some patients may have a more indolent presentation later in life. Bile acid synthesis disorders often present with normal or low levels of gamma-glutamyltranspeptidase and usually low levels of total serum bile acids, in contrast to other chronic cholestatic disorders. Rapid diagnosis of potential inborn errors in bile acid synthesis from urinary bile acid analysis is suggested. Molecular techniques could then identify the specific mutations in genes encoding the enzymes responsible for bile acid synthesis. [44] [45] [46] Treatment with the end products of bile acid synthesisdcholic acid and chenodeoxycholic aciddis often a curative for several bile acid synthesis disorders.
Genomic Testing for Hereditary Cholestasis Liver Disease in Clinical Practice
The identification of mutations in known chronic cholestasiserelated genes has allowed a complete reclassification of these diseases. This has led to better evaluation of clinical outcomes and prognosis of these patients. Recent developments in genomic methodologies, including WES, is changing the landscape of assessment of on patients with chronic cholestasis of hereditary etiology. In our own practice, such patients first meet with a certified genetic counselor of the IM clinic to inform about the expectations and limitations of genomic testing. Then, we offer these patients the Emory Genetics Laboratory "gene panel" testing for cholestasis, which includes 66 genes relevant to neonatal and adult cholestatic conditions (Table 4) . If testing of a patient for the gene panel identifies a specific mutation, then a diagnosis is made. For patients with negative gene panel test results, we offer CAP/CLIA-certified WES aiming at the identification of novel genes that could explain the cholestatic condition. Whole exome sequencing could include additional relatives of the patient (affected or unaffected) in an effort to maximize the discovery of the genes contributing to the cholestatic phenotype. The results of the gene panel testing and WES are discussed at the GOB, and the resulting recommendations are provided to the referring physician and patient. For patients with positive genomic test results, a follow up meeting with a certified genetic counselor is provided and further screening of family members is suggested as indicated.
FAMILIAL COLON CANCER SYNDROMES
Colorectal cancer (CRC) is the third most commonly diagnosed cancer and the third leading cause of cancer deaths in the United States. Although most CRCs appear to be sporadic age-related cancers (mean age at diagnosis, 65 years), approximately 20% of CRCs occur in familial aggregates, having varying patterns of apparent disease penetrance and inheritance (Table 5) . 52 Among the CRCs with a familial component, known genetic conditions account for a small fraction of these patients. The 2 best characterized familial syndromesdLynch syndrome (LS) and familial adenomatous polyposis (FAP)dare autosomal dominant inherited disorders and account for approximately 2% and 0.1% to 1% of all CRCs, respectively. Genetic testing for LS may be approached through tumor (somatic events) to direct chemotherapeutic treatments for all patients with CRC as well as to provide guidance for germline testing for patients with LS CRC. Direct germline sequencing of the DNA mismatch repair (MMR) genes may be used as the first line assessment for LS, too. For FAP, somatic testing is not used, and germline testing for mutations in adenomatous polyposis coli (APC) and MutY (E. coli) homolog (MYH) genes may be pursued for patients who have a clinical phenotype of FAP. However, more recently hereditary (germline) CRC NGS panels to evaluate all the genes known to cause inherited CRC are also being used as the first line of evaluation for patients suspected to have an increased risk of familial CRC.
Lynch Syndrome
Lynch syndrome is the most common autosomal dominant inherited CRC syndrome and results from germline mutations in the DNA MMR genes mutL homolog 1 (MLH1), mutS homolog 2 (MSH2), mutS homolog 6 (MSH6), and PMS1 homolog 2 (PMS2). Inactivation of the MMR genes allows replicationrelated base pair mistakes to go uncorrected and manifests as infidelity in mono-, di-, and trinucleotide repeat areas throughout the genome known as microsatellite instability. 53, 54 These tumors are termed deficient mismatch repair (dMMR) as opposed to most CRCs, which have proficient mismatch repair (pMMR). Deletion of epithelial cell adhesion molecule, a gene contiguous to MSH2, can result in hypermethylation of MSH2 and is another source of dMMRrelated CRC. 55 However, up to 20% of dMMR CRCs result from acquired hypermethylation of mutL homolog 1 (hMLH1). Hypermethylation of hMLH1 develops more frequently with increasing age 56 and is not known to have an underlying germline genetic predisposition, 57 though a case of germlinerelated MLH1 hypermethylation has been reported. 58 Deficient mismatch repair genes secondary to MLH1 hypermethylation may be evaluated through cascade tumor testing to assess for hypermethylation of the MLH1 gene and/or the presence of BRAF-V600E mutations in tumors with absent expression of MLH1 on tumor immunostaining, which indicates that it is unlikely that the patient has LS.
In both hereditary and acquired dMMR CRCs, the tumor DNA is characterized by genome-wide hypermutability exceeding 20-fold that seen in pMMR CRCs. This phenomenon caused a significant cancer antigen burden, which promotes activation of the immune system of the patient with dMMR CRC and may explain the improved prognosis reported for Peroxisomal biogenesis factor 5 PEX6 Peroxisomal biogenesis factor 6 PEX7 Peroxisomal biogenesis factor 7 PKHD1
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Continued on next page germline and, though controversial, acquired dMMR CRC patients. 59, 60 This interaction of the host immune cancer fighting response has recently been targeted with immunotherapy via programmed death-ligand 1 blockade that has resulted in significant improvements in survival for all dMMR-related cancers. 61 Tumor testing affects several crucial clinical treatment questions addressed in the National Comprehensive Cancer Network recommendation 62 that all patients with CRC should undergo tumor testing with immunohistochemistry staining of the 4 DNA MMR genes and/or microsatellite instability testing. Recognition of LS before surgery is beneficial because surgical recommendations for patients with LS with colon (but not rectal) cancer include a discussion of more extensive surgery such as ileosigmoidostomy or ileorectostomy, and for women with LS after childbearing, the possibility of hysterectomy and oophorectomy at the time of colorectal surgery.
Biallelic Mismatch Repair Deficiency Syndrome
Biallelic mismatch repair deficiency syndrome is a relatively recently recognized syndrome that carries a high risk of multiple cancer types. 63 People who inherit biallelic mutations in any of the MMR genes typically develop cancers at a young age and are at risk of developing at least 1 additional cancer in their lifetime. Hematological cancers, particularly T-cell lymphoma, CRC, and small bowel cancers, are the predominant malignant neoplasms. Brain tumors including high-grade gliomas, primitive neuroectodermal tumors, and medulloblastomas may also arise in childhood and may account for at least a proportion of the cases of Turcot syndrome. Café-au-lait spots are a hallmark of this condition and may be mistaken as evidence of a diagnosis of neurofibromatosis type 1. 63 Twothirds of patients with biallelic mismatch repair deficiency syndrome who do not develop cancer until adulthood will present with CRC, and this may be in the setting of multiple colonic polyps that may phenotypically resemble a patient with FAP.
Familial CRC Syndrome Type X Familial CRC syndrome type X refers to kindreds who are at risk of LS according to Amsterdam criteria (AC) but who have pMMR CRC. Lindor et al 64 found that in kindreds meeting AC and have pMMR CRC, the standardized incidence ratio of CRC was 2.3 for first-degree relatives not in the original triad who met AC. Notably, among the kindreds with familial CRC syndrome type X, only the risk of CRC was increased, as opposed to kindreds with LS, in whom other cancers including those of the endometrium, ovaries, pancreas, biliary tree, and renal pelvis and upper collecting system of the urinary tract were also increased. 64 The genetic etiology for patients with familial CRC syndrome type X and pMMR young onset CRC remains elusive.
Familial Adenomatous Polyposis
Familial adenomatous polyposis is an autosomal dominant hereditary polyposis syndrome characterized by hundreds to thousands of colorectal polyps. Most patients develop the syndrome because of a germline mutation in the APC gene on chromosome 5q21, with up to one-third of APC-related FAP arising from de novo mutations. 48 Nearly 100% of patients with fulminant FAP develop CRC by the age of 40. Fortunately, FAP is rare, with an incidence of 1 in 6850 to 1 in 31,250 live births and accounts for less than 1% of all CRCs. 65 Germline truncating mutations in the APC tumor suppressor gene are detectable in more than 90% of patients with classic FAP. 66 Gardner syndrome refers to FAP with the additional findings of osteomas, sebaceous cysts, lipomas, desmoids, and dental abnormalities 67 and is caused by mutations in the APC gene. Although previously regarded as a phenomenon distinct from FAP, Gardner syndrome is now recognized a subtype of FAP in which these extraintestinal phenotypic manifestations accompany colonic polyposis.
Turcot syndrome is a rare manifestation of germline APC mutations that results in malignancies of the central nervous system in association with colonic polyposis. 68 Phenotypic expression in families with APC-related Turcot syndrome is variable, and within the same kindred, APC mutation carriers may develop both colonic polyposis and medulloblastomas, whereas others exclusively manifest colonic polyposis or early-onset brain malignancies.
Attenuated FAP
Another variant of FAP, referred to as attenuated familial adenomatous polyposis (AFAP), features the development of fewer than 100 polyps. These polyps tend to cluster in the proximal colon and develop at an older age of onset, with malignant transformation occurring 10 to 20 years later than for those affected with classic FAP. Approximately 40% of patients with AFAP have germline APC mutations. 69 
MUTYH (or MYH) Adenomatous Polyposis
Adenomatous polyposis mimicking both FAP and AFAP may be due to germline biallelic MYH mutations that lead to colorectal polyposis and an increased risk of CRC. 70, 71 Inactivation of MYH, which functions as a base excision repair mechanism to correct oxidation-related mutations, leads to somatic G:C to T:A transversions in APC and likely accounts for the clinical picture that resembles that of patients with germline APC mutations. Because of this phenotypic overlap, patients with clinical FAP or AFAP may undergo either simultaneous or cascade testing for both APC and MYH mutations.
Polyposis Syndromes
Although LS-related CRC arises from a polyp, historically LS is classified as a nonpolyposis syndrome to distinguish it from most other hereditary CRC syndromes that tend to have a higher polyp burden. The other polyposis syndromes represent a heterogeneous group of conditions that predispose patients to a higher risk of colorectal and extracolonic malignancies. The malignant precursor lesions include adenomatous polyps, serrated adenomatous polyps, and several different classifications of hamartomatous polyps. The clinical phenotypes for these conditions are so heterogeneous that making a solely clinically based diagnosis is extremely challenging. The known hereditary conditions include FAP, attenuated FAP, MutYH (or MYH) adenomatous polyposis, juvenile polyposis syndrome, which may have overlap with hereditary hemorrhagic telangiectasia, Peutz-Jeghers syndrome, PTEN hamartoma tumor syndrome, NTHL adenomatous polyposis, polymerase proofreading adenomatous polyposis, serrated polyposis syndrome, and hereditary mixed polyposis syndrome. Underlying germline genetic aberrations have been identified for all these syndromes except serrated polyposis syndrome, are often associated with a risk of extracolonic cancers, and form the basis for hereditary or familial colon cancer gene panels (Table 5) . Inflammatory cap polyposis and Cronkhite-Canada (Table 6 ). For those patients tested for the colon cancer gene panel with no causative mutations identified on this testing, WES is performed with the goal to discover novel germline variants that predispose an individual to develop young onset CRC. The results of WES are reviewed at the GOB, and recommendations are provided to the patients and referring physicians with the help of a certified genetic counselor. We anticipate that through this approach, actionable genetic results may be determined. These findings may have an immediate effect on the at-risk family members of the proband so as to inform appropriate CRC and other related cancer screening recommendations. Similarly, if pathogenic genetic variants are identified, these will provide the basis for expanding familial CRC gene panels and further our understanding of the pathways that underlie malignant transformation in the colorectum.
CONCLUSION
Over the past decade the genetic basis of selected digestive diseases has been elucidated. These advances coupled with the availability of NGS methodologies for clinical testing will further the genomic understanding of several gastrointestinal tract and liver diseases, with the potential to improve prognostication in and therapies for these patients.
Abbreviations and Acronyms: AC = Amsterdam criteria; AFAP = attenuated familial adenomatous polyposis; APC = adenomatous polyposis coli; CAP = College of American Pathologists; CD = Crohn disease; CLIA = Clinical Laboratory Improvement Amendments; CRC = colorectal cancer; dMMR = deficient mismatch repair; EHR = electronic health record; FAP = familial adenomatous polyposis; GOB = genomics odyssey board; IBD = inflammatory bowel disease; IM = Individualized Medicine; LRBA = lipopolysaccharide responsive beige-like anchor; LS = Lynch syndrome; MDR3 = multidrug resistance 3; MLH1 = mutL homolog 1; MMR = mismatch repair; MUTYH or MYH = MutY (E. coli) homolog; NGS = next-generation sequencing; PFIC = progressive familial intrahepatic cholestasis; pMMR = proficient mismatch repair; UC = ulcerative colitis; VEOIBD = very early onset inflammatory bowel disease; WES = whole exome sequencing The Symposium on Precision Medicine will continue in an upcoming issue.
